Valuation: EnteroMedics Inc

Market Cap 16.14M 14.11M 12.97M 12.09M 22.93M 1.54B 23.28M 156M 60.53M 756M 60.59M 59.29M 2.6B P/E 2026 *
-3.26x
P/E 2027 * -2.51x
Enterprise Value 16.14M 14.11M 12.97M 12.09M 22.93M 1.54B 23.28M 156M 60.53M 756M 60.59M 59.29M 2.6B EV / Sales 2026 *
108x
EV / Sales 2027 * 64.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 131K 121K 112K 213K 14.28M 216K 1.45M 562K 7.02M 563K 551K 24.19M 250K 219K 201K 187K 355K 23.8M 360K 2.41M 937K 11.7M 938K 918K 40.32M
Net income -4.89M -4.27M -3.93M -3.66M -6.95M -466M -7.05M -47.16M -18.33M -229M -18.36M -17.96M -789M -7.77M -6.79M -6.24M -5.82M -11.03M -740M -11.2M -74.93M -29.13M -364M -29.16M -28.54M -1.25B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-